Literature DB >> 3165484

[Virus-specific antibody profile in various stages of HIV-1 infection. Western blot analysis of 170 patients].

C Schulte1, M Meurer, O Braun-Falco, M Held, M Fröschl.   

Abstract

The western blot analysis of 170 patients with HIV-1-infection demonstrated that 47% of the patients in latent stage, 58% of the patients with lymphadenopathy-syndrome and only 25% of the patients with the full-blown picture of AIDS showed the complete pattern of HIV-specific antibody response. This antibody response is mainly directed against the env-encoded envelope proteins gp160, gp120 and gp41, against the gag-encoded core proteins p55, p24 and p17 as well as against the pol-encoded enzymatic proteins p66, p51 and p31. Antibodies against gp160 and gp120 were present in nearly all patients, whereas the prevalence of the other antibodies decreased with the stage of the disease. Statistical significant differences were found particularly between patients with LAS or AIDS respectively. Antibodies against p17 were detected in 74% of the patients with LAS but only in 25% of the patients with AIDS. The lack of antibodies against p17, p24 or p51 was significantly associated with lower mean CD4/CD8-ratios (p less than 0.007) and higher mean serum levels of IgA (p less than 0.001) and beta-2-microglobulin (p less than 0.001). One third of the patients with LAS and this reduced pattern of antibody response developed AIDS within six months. These results demonstrate that the detection of antibodies against p17, p24 or p51 is of prognostic importance. A serological profile which lacks the antibody response against at least two of those three viral antigens indicates a progression of the disease activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3165484     DOI: 10.1007/bf01876170

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  23 in total

1.  Beta 2-microglobulin as a prognostic marker for development of AIDS.

Authors:  R B Bhalla; B Safai; S Pahwa; M K Schwartz
Journal:  Clin Chem       Date:  1985-08       Impact factor: 8.327

2.  Serological characterization of HTLV-III infection in AIDS and related disorders.

Authors:  J E Groopman; F W Chen; J A Hope; J M Andrews; R L Swift; C V Benton; J L Sullivan; P A Volberding; D P Sites; S Landesman
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

3.  Patterns of antibody response in individuals infected with the human immunodeficiency virus.

Authors:  L Z Pan; C Cheng-Mayer; J A Levy
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

4.  Diagnostic significance of quantitative determination of HIV antibody specific for envelope and core proteins.

Authors:  G G Frösner; V Erfle; W Mellert; R Hehlmann
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

5.  Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis.

Authors:  V C Tsang; J M Peralta; A R Simons
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

Authors:  A Ranki; S H Weiss; S L Valle; J Antonen; K J Krohn
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

7.  Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome.

Authors:  S Vadhan-Raj; G Wong; C Gnecco; S Cunningham-Rundles; M Krim; F X Real; H F Oettgen; S E Krown
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

8.  Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection.

Authors:  A Ranki; S L Valle; M Krohn; J Antonen; J P Allain; M Leuther; G Franchini; K Krohn
Journal:  Lancet       Date:  1987-09-12       Impact factor: 79.321

9.  Methods in laboratory investigation. Application of the indirect enzyme-linked immunosorbent assay microtest to the detection and surveillance of human t cell leukemia-lymphoma virus.

Authors:  C Saxinger; R C Gallo
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

10.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.